Christensenella

Unique Gut Bacteria with Deep Therapeutic Benefit Potential

Since its discovery in 2012, the christensenella group of gut bacteria has continuously demonstrated high potential in the field of human health.

 

Christensenella minuta was discovered in 2012 by Professor Masami Morotomi (Yakult Central Institute for Microbiological Research, Japan) who isolated the small micro-organism from a healthy human donor.

In 2014, it was identified as the most heritable bacterial taxon in humans and was found to be significantly reduced in obese European individuals (Goodrich et al. 2014).

These observations were rapidly confirmed in an independent study in 2015 (Fu et al. 2015). In addition, high levels of C. minuta in the 2015 cohort were associated with reduced circulating levels of triglycerides and higher HDL cholesterol (also known as “good” cholesterol).

more +

This association was recently validated in a large Dutch cohort of more than 2000 people where Christensenellaceae were consistently associated with low VLDL (“bad cholesterol”), high HDL (“good cholesterol”) and low serum triglycerides (Vojinovic et al. 2019).

Disappearance of C. minuta bacteria has also been associated with other conditions such as Inflammatory Bowel Disease (IBD), both with Crohn’s Disease and Ulcerative Colitis (Pascal et al. 2017, Kummen et al. 2017, Zakrzewski et al. 2018), Primary Sclerosing Cholangitis (PSC) (Kummen et al. 2017) and Irritable Bowel Syndrome (IBS) (Pozuelo et al. 2015). 

Although many questions remain to be explored, there is an increasing body of evidence that Christensenellaceae play a major role in the development of a healthy intestinal microbiome and is absent in many pathological conditions. Thus, it bears high potential to be a source of innovative treatment for multiple diseases.

Microbiome & us
News
Feb 3, 2020
We are looking for Administrative and Finance Assistant | WHAT WE OFFER An exciting opportunity to dive in and begin...
> more
Jan 13, 2020
We are looking for Clinical Project Manager | WHAT WE OFFER An exciting opportunity to dive in and begin your career...
> more
Press / Media
Nov 12, 2019
Biotechs investments disrupt Big Pharma business model The pharmaceutical industry is in a state of flux, with...
> more
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Publications
Dec 6, 2019
The term “microbiome” refers to the collection of microorganisms (or microbiota) – including bacteria, viruses and...
> more
Oct 28, 2019
Jillian L. Waters, Ruth E. Ley The Christensenellaceae, a recently described family in the phylum Firmicutes, is emerging...
> more
now on twitter
LNC Therapeutics

In a large human study Dr Katerina Johnson found that both gut microbiome composition and diversity were related to… t.co/eufMEnGuo4

LNC Therapeutics © 2020 - all rights reserved terms and conditions